A clinical trial of ADG20 in the pediatric population aged two and 11 years
Latest Information Update: 29 Sep 2022
At a glance
- Drugs Adintrevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Invivyd
- 12 Sep 2022 According to an Adagio Therapeutics media release, Adagio Therapeutics has changed its name to Invivyd.
- 03 Dec 2021 New trial record
- 15 Nov 2021 According to an Adagio Therapeutics media release, following discussion with the FDA the company plans to initiate by mid-year 2022.